Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Hawai'I Journal of Medicine & Public Health : a Journal of Asia Pacific Medicine & Public Health
|
March 29, 2012
Science in liquid dietary supplement promotion: the misleading case of mangosteen juice
Ano L Lobb
The International Journal of Neuroscience
|
August 1, 1986
Pattern of eyelid motion predictive of decision errors during drowsiness: oculomotor indices of altered states
M L Lobb, J A Stern
The Psychiatric Quarterly
|
July 1, 2010
Recovery-oriented training and staff attitudes over time in two state hospitals
Jack Tsai, Michelle P Salyers, Angela L Lobb
Perceptual and Motor Skills
|
October 1, 1984
A behavioral technique for recovery from the psychological trauma of hysterectomy
M L Lobb, M C Shannon, S L Recer, et al.
Developmental Medicine and Child Neurology
|
January 29, 2003
Reliability and validity of the Observational Gait Scale in children with spastic diplegia
Anna H Mackey, Glenis L Lobb, Sharon E Walt, et al.
Protein Engineering
|
December 1, 1996
Expression, purification and characterization of recombinant crambin
L Lobb, B Stec, E K Kantrowitz, et al.
Life Sciences
|
January 1, 1997
The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs
L A Phebus, K W Johnson, P W Stengel, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 28, 2026
Curated set of tool compounds to probe PYK2 and FAK signaling in Alzheimer's disease
Pathum M Weerawarna, Cynthia D Jesudason, Karen L Lobb, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 27, 2001
Expedited discovery of second generation NK-1 antagonists: identification of a nonbasic aryloxy substituent
J E Fritz, P A Hipskind, K L Lobb, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 1, 1995
Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist
B D Gitter, R F Bruns, J J Howbert, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Hawai'I Journal of Medicine & Public Health : a Journal of Asia Pacific Medicine & Public Health
|
March 29, 2012
Science in liquid dietary supplement promotion: the misleading case of mangosteen juice
Ano L Lobb
The International Journal of Neuroscience
|
August 1, 1986
Pattern of eyelid motion predictive of decision errors during drowsiness: oculomotor indices of altered states
M L Lobb, J A Stern
The Psychiatric Quarterly
|
July 1, 2010
Recovery-oriented training and staff attitudes over time in two state hospitals
Jack Tsai, Michelle P Salyers, Angela L Lobb
Perceptual and Motor Skills
|
October 1, 1984
A behavioral technique for recovery from the psychological trauma of hysterectomy
M L Lobb, M C Shannon, S L Recer, et al.
Developmental Medicine and Child Neurology
|
January 29, 2003
Reliability and validity of the Observational Gait Scale in children with spastic diplegia
Anna H Mackey, Glenis L Lobb, Sharon E Walt, et al.
Protein Engineering
|
December 1, 1996
Expression, purification and characterization of recombinant crambin
L Lobb, B Stec, E K Kantrowitz, et al.
Life Sciences
|
January 1, 1997
The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs
L A Phebus, K W Johnson, P W Stengel, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 28, 2026
Curated set of tool compounds to probe PYK2 and FAK signaling in Alzheimer's disease
Pathum M Weerawarna, Cynthia D Jesudason, Karen L Lobb, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 27, 2001
Expedited discovery of second generation NK-1 antagonists: identification of a nonbasic aryloxy substituent
J E Fritz, P A Hipskind, K L Lobb, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 1, 1995
Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist
B D Gitter, R F Bruns, J J Howbert, et al.
Page
of 2